Elentina K Argyrousi
Overview
Explore the profile of Elentina K Argyrousi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
187
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Castranio E, Varghese M, Argyrousi E, Tripathi K, Soderberg L, Bresnahan E, et al.
bioRxiv
. 2025 Mar;
PMID: 40060689
Teaser: APP "NFA-Aβ only" mice reveal clinically relevant mechanisms despite the absence of detectable inflammation.
2.
Fioriti L, Wijesekara N, Argyrousi E, Matsuzaki S, Takamura H, Satoh K, et al.
Alzheimers Dement
. 2025 Mar;
21(3):e70030.
PMID: 40047257
Introduction: Amyloid beta oligomers (Aβos) are toxic to synapses and key to the progression of Alzheimer's disease (AD) and amyloid pathology, representing a target for therapeutic strategies. Methods: Amyloid and...
3.
Bay S, Rodina A, Haut F, Roychowdhury T, Argyrousi E, Staniszewski A, et al.
Res Sq
. 2025 Feb;
PMID: 39989971
Alzheimer's disease (AD) progresses as a continuum, from preclinical stages to late-stage cognitive decline, yet the molecular mechanisms driving this progression remain poorly understood. Here, we provide a systems-level map...
4.
Ribeiro F, Cozachenco D, Argyrousi E, Staniszewski A, Wiebe S, Calixtro J, et al.
Alzheimers Dement
. 2024 Jun;
20(8):5398-5410.
PMID: 38934107
Introduction: Impaired brain protein synthesis, synaptic plasticity, and memory are major hallmarks of Alzheimer's disease (AD). The ketamine metabolite (2R,6R)-hydroxynorketamine (HNK) has been shown to modulate protein synthesis, but its...
5.
Acquarone E, Argyrousi E, van den Berg M, Gulisano W, Fa M, Staniszewski A, et al.
Mol Neurodegener
. 2024 Apr;
19(1):39.
PMID: 38685083
No abstract available.
6.
Cortese G, Bartosch A, Xiao H, Gribkova Y, Lam T, Argyrousi E, et al.
J Neuropathol Exp Neurol
. 2024 Apr;
83(7):626-635.
PMID: 38630575
ZCCHC17 is a master regulator of synaptic gene expression and has recently been shown to play a role in splicing of neuronal mRNA. We previously showed that ZCCHC17 protein declines...
7.
DAcunzo P, Argyrousi E, Ungania J, Kim Y, DeRosa S, Pawlik M, et al.
Mol Neurodegener
. 2024 Apr;
19(1):34.
PMID: 38616258
Background: Hypometabolism tied to mitochondrial dysfunction occurs in the aging brain and in neurodegenerative disorders, including in Alzheimer's disease, in Down syndrome, and in mouse models of these conditions. We...
8.
Acquarone E, Argyrousi E, Arancio O, Watterson D, Roy S
J Alzheimers Dis
. 2024 Apr;
98(4):1349-1360.
PMID: 38578894
Background: Background: Neurodegenerative diseases manifest behavioral dysfunction with disease progression. Intervention with neuropsychiatric drugs is part of most multi-drug treatment paradigms. However, only a fraction of patients responds to the...
9.
Haut F, Argyrousi E, Arancio O
Int J Mol Sci
. 2024 Jan;
25(1).
PMID: 38203429
After several years of research in the field of Alzheimer's disease (AD), it is still unclear how amyloid-beta (Aβ) and Tau, two key hallmarks of the disease, mediate the neuropathogenic...
10.
Dridi H, Liu Y, Reiken S, Liu X, Argyrousi E, Yuan Q, et al.
Nat Neurosci
. 2023 Jul;
26(8):1365-1378.
PMID: 37429912
Cognitive dysfunction (CD) in heart failure (HF) adversely affects treatment compliance and quality of life. Although ryanodine receptor type 2 (RyR2) has been linked to cardiac muscle dysfunction, its role...